Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: A report from the Chinese Atrial Fibrillation Registry study
- PMID: 33269504
- DOI: 10.1111/jce.14826
Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: A report from the Chinese Atrial Fibrillation Registry study
Abstract
Background: An understanding of the risk factors for atrial fibrillation (AF) progression and the associated impacts on clinical prognosis are important for the future management of this common arrhythmia. We aimed to investigate the rate of progression from paroxysmal (PAF) to more sustained subtypes of AF (SAF), the associated risk factors for this progression, and its impact on adverse clinical outcomes.
Methods and results: Using data from the Chinese trial Fibrillation Registry study, we included 8290 PAF patients. Half of them underwent initial AF ablation at enrollment. The main outcomes were ischemic stroke/systemic embolism (IS/SE), cardiovascular hospitalization, cardiovascular death, and all-cause mortality. The median follow-up duration was 1091 (704, 1634) days, and progression from PAF to SAF occurred in 881 (22.5%) nonablated patients, while 130 (3.0%) ablated patients had AF recurrence and developed SAF. The incidence rate of AF progression for the cohort was 3.87 (95% confidence interval [CI] = 3.64-4.12) per 100 patient-years, being higher in nonablated compared to ablated patients. Older age, longer AF history, heart failure, hypertension, coronary artery disease, respiratory diseases, and larger atrial diameter were associated with a higher incidence of AF progression, while antiarrhythmic drug use and AF ablation were inversely related to it. For nonablated patients, AF progression was independently associated with an increased risk of IS/SE (hazard ratio [HR] = 1.52, 95% CI = 1.15-2.01) and cardiovascular hospitalizations (HR = 1.40, 95% CI = 1.23-1.58).
Conclusion: AF progression was common in its natural course. It was related to comorbidities and whether rhythm control strategies were used, and was associated with an increased risk of IS/SE and cardiovascular hospitalization.
Keywords: ablation; atrial fibrillation; prognosis; progression; risk factor.
© 2020 Wiley Periodicals LLC.
Similar articles
-
Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events.Stroke. 2018 Oct;49(10):2301-2308. doi: 10.1161/STROKEAHA.118.021396. Stroke. 2018. PMID: 30355097
-
Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693. JAMA. 2019. PMID: 30874766 Free PMC article. Clinical Trial.
-
Clinical Impact of Asymptomatic Presentation Status in Patients With Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry.Chest. 2017 Dec;152(6):1266-1275. doi: 10.1016/j.chest.2017.08.004. Epub 2017 Aug 16. Chest. 2017. PMID: 28823813 Clinical Trial.
-
Atrial fibrillation progression and the importance of early treatment for improving clinical outcomes.Europace. 2022 Jun 6;24(Suppl 2):ii22-ii28. doi: 10.1093/europace/euab257. Europace. 2022. PMID: 35661866 Review.
-
Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: A meta-analysis.J Cardiovasc Electrophysiol. 2020 May;31(5):1040-1047. doi: 10.1111/jce.14429. Epub 2020 Mar 9. J Cardiovasc Electrophysiol. 2020. PMID: 32115777
Cited by
-
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J Am Coll Cardiol. 2024 Jan 2;83(1):109-279. doi: 10.1016/j.jacc.2023.08.017. Epub 2023 Nov 30. J Am Coll Cardiol. 2024. PMID: 38043043 Free PMC article.
-
Liraglutide inhibits AngII-induced cardiac fibroblast proliferation and ECM deposition through regulating miR-21/PTEN/PI3K pathway.Cell Tissue Bank. 2023 Mar;24(1):125-137. doi: 10.1007/s10561-022-10021-9. Epub 2022 Jul 6. Cell Tissue Bank. 2023. PMID: 35792987
-
Pulsed Field Ablation of Atrial Fibrillation: A Novel Technology for Safer and Faster Ablation.Biomedicines. 2024 Sep 30;12(10):2232. doi: 10.3390/biomedicines12102232. Biomedicines. 2024. PMID: 39457545 Free PMC article. Review.
-
Effect of Air Quality on the Risk of Emergency Room Visits in Patients With Atrial Fibrillation.Front Cardiovasc Med. 2021 May 11;8:672745. doi: 10.3389/fcvm.2021.672745. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34046441 Free PMC article.
-
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30. Circulation. 2024. PMID: 38033089 Free PMC article.
References
REFERENCES
-
- Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease? J Am Coll Cardiol. 2017;69(15):1968-82.
-
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.
-
- Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation. 2007;115(24):3050-3056.
-
- Blum S, Aeschbacher S, Meyre P, et al. Incidence and predictors of atrial fibrillation progression. J Am Heart Assoc. 2019;8(20):e012554.
-
- de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55(8):725-731.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical